Lack of TNFα mRNA expression in cervical cancer is not associated with loss of heterozygosity at 6p21.3, inactivating mutations or promoter methylation

Molecular Immunology

Volumn 45, Issue 1, 2008, Pages 152-159

  Kloth, Judith N ^a   Gorter, Arko ^a   Haar, Natalja ter ^a   Corver, Willem E ^a   Jordanova, Ekaterina S ^a   Kenter, Gemma G ^a   Fleuren, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Cytokines; Loss of heterozygosity; Tumor suppressor gene

Indexed keywords

MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; MICROSATELLITE DNA;

ALLELE; ARTICLE; CARCINOGENESIS; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; CHROMOSOME 6; CPG ISLAND; DNA METHYLATION; EXON; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS;

ALLELES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 6; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MUTATION; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 34548249637     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.04.028     Document Type: Article

References (36)

1. Abeln E.C., Corver W.E., Kuipers-Dijkshoorn N.J., Fleuren G.J., and Cornelisse C.J. Molecular genetic analysis of flow-sorted ovarian tumour cells: improved detection of loss of heterozygosity. Br. J. Cancer 70 (1994) 255-262
2. Abraham L.J., and Kroeger K.M. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J. Leukoc. Biol. 66 (1999) 562-566
3. Calhoun E.S., McGovern R.M., Janney C.A., Cerhan J.R., Iturria S.J., Smith D.I., Gostout B.S., and Persing D.H. Host genetic polymorphism analysis in cervical cancer. Clin. Chem. 48 (2002) 1218-1224
4. Chatterjee A., Pulido H.A., Koul S., Beleno N., Perilla A., Posso H., Manusukhani M., and Murty V.V. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions. Cancer Res. 61 (2001) 2119-2123
5. Corver W.E., Ter Haar N.T., Dreef E.J., Miranda N.F., Prins F.A., Jordanova E.S., Cornelisse C.J., and Fleuren G.J. High-resolution multi-parameter DNA flow cytometry enables detection of tumor and stromal cell subpopulations in paraffin-embedded tissues. J. Pathol. 206 (2005) 233-241
6. Deshpande A., Nolan J.P., White P.S., Valdez Y.E., Hunt W.C., Peyton C.L., and Wheeler C.M. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J. Infect. Dis. 191 (2005) 969-976
7. Duarte I., Santos A., Sousa H., Catarino R., Pinto D., Matos A., Pereira D., Moutinho J., Canedo P., Machado J.C., and Medeiros R. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem. Biophys. Res. Commun. 334 (2005) 588-592
8. El Sherif A.M., Seth R., Tighe P.J., and Jenkins D. Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J. Pathol. 195 (2001) 179-185
9. Giannini S.L., Al Saleh W., Piron H., Jacobs N., Doyen J., Boniver J., and Delvenne P. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin. Exp. Immunol. 113 (1998) 183-189
10. Haudek S.B., Natmessnig B.E., Redl H., Schlag G., and Giroir B.P. Genetic sequences and transcriptional regulation of the TNFA promoter: comparison of human and baboon. Immunogenetics 48 (1998) 202-207
11. Haven C.J., van Puijenbroek M., Karperien M., Fleuren G.J., and Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J. Pathol. 202 (2004) 86-94
12. Hazelbag S., Fleuren G.J., Baelde J.J., Schuuring E., Kenter G.G., and Gorter A. Cytokine profile of cervical cancer cells. Gynecol. Oncol. 83 (2001) 235-243
13. Ho S.Y., Wang Y.J., Chen H.L., Chen C.H., Chang C.J., Wang P.J., Chen H.H., and Guo H.R. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control 15 (2004) 657-663
14. Jordan L.B., and Monaghan H. Pathology of the cervix: recent developments. Clin. Oncol. (R. Coll. Radiol.) 16 (2004) 248-254
15. Kersemaekers A.M., Kenter G.G., Hermans J., Fleuren G.J., and van de Vijver M.J. Allelic loss and prognosis in carcinoma of the uterine cervix. Int. J. Cancer 79 (1998) 411-417
16. Kirkpatrick A., Bidwell J., van den Brule A.J., Meijer C.J., Pawade J., and Glew S. TNFalpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol. Oncol. 92 (2004) 675-679
17. Kloth J.N., Fleuren G.J., Oosting J., de Menezes R.X., Eilers P.H., Kenter G.G., and Gorter A. Substantial changes in gene expression of Wnt MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines. Carcinogenesis 26 (2005) 1493-1502
18. Kochanek S., Radbruch A., Tesch H., Renz D., and Doerfler W. DNA methylation profiles in the human genes for tumor necrosis factors alpha and beta in subpopulations of leukocytes and in leukemias. Proc. Natl. Acad. Sci. U.S.A 88 (1991) 5759-5763
19. Koopman L.A., Szuhai K., van Eendenburg J.D., Bezrookove V., Kenter G.G., Schuuring E., Tanke H., and Fleuren G.J. Recurrent integration of human papillomaviruses 16 45 and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res. 59 (1999) 5615-5624
20. Kroeger K.M., Carville K.S., and Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 34 (1997) 391-399
21. Longworth M.S., and Laimins L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68 (2004) 362-372
22. Malejczyk M., Jozwiak J., Osiecka A., Roszkowski P.I., Mazurkiewicz-Smoktunowicz W., Rogozinski T.T., Walczak L., Jablonska S., Majewski S., and Malejczyk J. Serum levels of soluble tumor-necrosis-factor receptors in patients with benign and malignant HPV-associated anogenital lesions. Int. J. Cancer 73 (1997) 16-19
23. Miura T.A., Morris K., Ryan S., Cook J.L., and Routes J.M. Adenovirus E1A, not human papillomavirus E7, sensitizes tumor cells to lysis by macrophages through nitric oxide- and TNF-alpha-dependent mechanisms despite up-regulation of 70-kDa heat shock protein. J. Immunol. 170 (2003) 4119-4126
24. Pao C.C., Lin C.Y., Yao D.S., and Tseng C.J. Differential expression of cytokine genes in cervical cancer tissues. Biochem. Biophys. Res. Commun. 214 (1995) 1146-1151
25. Rangel R., Rocha L., Ramirez J.L., Ibarra M.J., Solorza G., Monroy A., Ramirez M.A., Herrera A., and Weiss-Steider B. Generation of memory CD4+, CD8+ CD45RO+and Eur. Cytokine Netw. 6 (1995) 195-202
26. Routes J.M., Morris K., Ellison M.C., and Ryan S. Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms. J. Virol. 79 (2005) 116-123
27. Ruiter D.J., Ferrier C.M., van Muijen G.N., Henzen-Logmans S.C., Kennedy S., Kramer M.D., Nielsen B.S., and Schmitt M. Quality control of immunohistochemical evaluation of tumor-associated plasminogen activators and related components European BIOMED-1 concerted action on clinical relevance of proteases in tumor invasion and metastasis. Eur. J. Cancer 34 (1998) 1334-1340
28. Scott M., Stites D.P., and Moscicki A.B. Th1 cytokine patterns in cervical human papillomavirus infection. Clin. Diagn. Lab. Immunol. 6 (1999) 751-755
29. Stanczuk G.A., Sibanda E.N., Tswana S.A., and Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int. J. Gynecol. Cancer 13 (2003) 148-153
30. Takei S., Fernandez D., Redford A., and Toyoda H. Methylation status of 5'-regulatory region of tumor necrosis factor alpha gene correlates with differentiation stages of monocytes. Biochem. Biophys. Res. Commun. 220 (1996) 606-612
31. Tchurikov N.A. Molecular mechanisms of epigenetics. Biochemistry (Mosc.) 70 (2005) 406-423
32. Wang S.S., and Hildesheim A. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J. Natl. Cancer Inst. Monogr. (2003) 35-40
33. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., and Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U.S.A 94 (1997) 3195-3199
34. Wu W.S., and McClain K.L. DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in Langerhans cell histiocytosis (LCH). J. Interferon Cytokine Res. 17 (1997) 631-635
35. Zagariya A., Mungre S., Lovis R., Birrer M., Ness S., Thimmapaya B., and Pope R. Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun. Mol. Cell Biol. 18 (1998) 2815-2824
36. Zijlmans H.J., Fleuren G.J., Baelde H.J., Eilers P.H., Kenter G.G., and Gorter A. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 109 (2007) 556-565